Zoetis has spent the past decade as one of Wall Street’s favorite ways to play the rise of the “fur-baby” economy. This month, investors were reminded that even steady compounders can stumble. After reporting third-quarter results on Nov. 4, the animal-health specialist saw its shares plunge nearly 14% in a single session and they have kept sliding, leaving the stock more than a third below last December’s peak.
Beneath the dramatic price action, the numbers hardly look disastrous. Revenue in the third quarter rose 1% year over year to $2.4 billion, or 4% on an “organic operational” basis that strips out currency and portfolio changes. Adjusted earnings per share climbed 8% to $1.70, beating Wall Street’s $1.62 estimate. Net income grew 6% to $721 million, with margins that would make most pharmaceutical companies envious.
So why the rout? The short answer is that Zoetis nicked the growth story investors had been paying a premium for. Management trimmed its 2025 revenue outlook to a range of $9.4 billion to $9.475 billion, down from a prior forecast of $9.45 billion to $9.6 billion and below where many analysts had penciled in their models. That still implies a respectable 5.5% to 6.5% organic growth rate next year—but a notch lower than the high-single-digit trend that once underpinned the stock’s lofty valuation.
The more subtle issue lies in where the deceleration is showing up. Zoetis’s crown jewels are its companion-animal franchises: flea, tick and heartworm prevention drugs such as Simparica Trio, dermatology stalwarts like Apoquel and Cytopoint, and a new wave of monoclonal antibodies for osteoarthritis pain in dogs and cats, Librela and Solensia. Together, pet-related products account for the majority of revenue and an even larger share of the company’s equity story.
In the third quarter, that engine coughed. Companion-animal sales grew just 2% organically to about $1.65 billion, shy of the roughly $1.71 billion analysts expected. U.S. sales were flat year over year, with growth in parasiticides and dermatology offset by weakness in the osteoarthritis franchise. International pet-health revenue did better, up 4% organically, but not enough to soothe concerns that the U.S. market—the industry’s most profitable—may be maturing faster than hoped.
The osteoarthritis drugs are a particular sore spot. Librela and Solensia were supposed to be the next big leg of growth, offering long-acting pain relief for older pets and reinforcing Zoetis’s reputation for innovation. Instead, reports of possible side effects in some dogs have sparked social-media chatter and caution among veterinarians, contributing to a decline in U.S. sales for the franchise. Management insists the overall benefit-risk profile remains favorable, but investors have seen enough drug backlashes to know how hard it can be to put that kind of genie back in the bottle.
Livestock, once the heart of the business when Zoetis was still part of Pfizer, didn’t help either. Revenue from products for cattle, pigs and poultry fell around 4% on a reported basis, hurt by weak demand for swine and poultry medications and the earlier sale of a medicated feed-additive portfolio. In a quarter when investors were already nervous about cyclical exposure, the sight of declining farm-animal revenue only reinforced the impression of a company losing some of its growth swagger.
All of this landed on a stock that had already been gently de-rating for months. Back in late 2024, Zoetis traded at more than 30 times forward earnings, a valuation justified by its high-teens earnings growth, fat margins and the perceived resilience of pet spending. Earlier this year, Stifel Nicolaus downgraded the shares, warning that revenue growth could slow through 2027 as competition intensified in dermatology and other key niches. Merck’s Numelvi and Elanco’s new dermatology offerings have begun to nibble at Zoetis’s share of the vet’s prescription pad, particularly in Europe.
The Q3 wobble turned that gentle drift into a slide. In the three months through Nov. 19, Zoetis stock fell roughly 25%, even as revenue and margins held steady. The main culprit: multiple compression. The company’s forward price-to-earnings ratio now sits around 17–18, down from a 12-month average near 29 and well below the mid-20s to low-30s band that has been typical for most of the past decade.
By some measures, Zoetis no longer looks like an indulgence for growth purists. The shares change hands at roughly 14 times enterprise value to EBITDA and about six times sales, discounts of roughly a third compared with a year ago. Analysts’ average 12-month price target hovers just under $170, implying upside of more than 40% from recent levels, though that consensus is likely to drift as more post-earnings revisions filter through.
That sets up the question vexing many portfolio managers: Is this slump a buying opportunity, or evidence that Zoetis has quietly matured into a slower-growing, lower-multiple franchise?
The bullish case starts with the basic economics of the business, which remain enviable. Zoetis enjoys net margins north of 25%, a scale and distribution footprint few rivals can match, and a portfolio skewed toward chronic, recurring conditions that keep pets and farm animals on treatment for years. In 2024, the company grew revenue 11% on an operational basis and adjusted net income by 15%, returning more than $2.6 billion to shareholders through dividends and buybacks. Those cash-flow dynamics have not fundamentally changed.
The pipeline is not empty, either. Beyond the current suite of parasiticides and dermatology drugs, Zoetis is advancing additional pain therapies, kidney treatments and next-generation biologics that could sustain mid-single-digit to high-single-digit revenue growth over time. If management can deliver even 6% annual sales growth and hold margins roughly steady, earnings per share should be able to grow in the high single digits, helped along by modest share repurchases. At a forward multiple in the high teens, that profile is no longer heroic; it is almost pedestrian. For long-term investors who missed the stock on its first big run, that alone may be appealing.
The bear case is that Zoetis is still in the process of finding its new equilibrium. The slowdown in U.S. companion-animal sales may signal not just temporary noise around Librela and Solensia, but a more structural shift as pet owners become slightly more price-sensitive and competitors get more aggressive. Safety concerns around a flagship franchise can linger in the background for years, even if regulators ultimately side with the company. And management has acknowledged that 2026 gross margins could come under some pressure, a prospect that has already prompted several brokers to cut their price targets into the $130 to $160 range.
Our Take
For investors with a three- to five-year horizon, the more interesting question is not whether Zoetis will re-rate back to its former glory, but whether it needs to. A high-quality oligopolist earning close to 30% net margins, with a sticky customer base and a modest but durable growth runway, ought to deliver decent returns from a starting multiple below 20 times earnings. The risk is that growth slows further or competition bites harder than expected, forcing the market to treat Zoetis less like a secular compounder and more like a mature pharma company, with a corresponding further step down in valuation.
On balance, the recent “crash” looks less like a verdict of failure and more like the end of a perfection trade. Zoetis has gone from priced for flawless execution to priced for merely good execution. For patient investors willing to tolerate some near-term volatility, that gap between perception and reality may well be the opening they have been waiting for.
